))
Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, cardiology, women's health and more. And our CME library is continuously growing, every quarter.
R
ReachMD CME
1
Advancing Global Care with Emerging BTKi in Relapsed/Refractory CLL: Connecting Hematology Leaders to Worldwide Learners
CME credits: 0.50 Valid until: 29-03-2024 Claim your CME credit at https://reachmd.com/programs/cme/advancing-global-care-with-emerging-btki-in-relapsedrefractory-cll-connecting-hematology-leaders-to-worldwide-learners/14643/ The validation of targeted agent classes, driven by the emergence of BTK inhibitors as a highly effective therapeutic tool, …
CME credits: 0.50 Valid until: 26-03-2024 Claim your CME credit at https://reachmd.com/programs/cme/in-your-waiting-room-the-virtual-ibs-c-patient-clinical-experience/14955/ Despite advances in the treatment of irritable bowel syndrome with constipation (IBS-C), many patients are still struggling. Our experts, Drs. Darren Brenner and Brooks Cash, d…
CME credits: 0.25 Valid until: 24-03-2024 Claim your CME credit at https://reachmd.com/programs/cme/addressing-the-challenge-in-rechallenge-strategies-for-mcrc/14483/ Are you familiar with rechallenge strategies with anti-EGFR therapies to treat metastatic colorectal cancer? Listen as Drs. Fortunato Ciardiello and Erika Martinelli discuss patients …
CME credits: 1.00 Valid until: 23-03-2024 Claim your CME credit at https://reachmd.com/programs/cme/btki-breakthroughs-overcoming-treatment-resistance-in-cll-mcl/14825/ Bruton’s tyrosine kinase inhibitors (BTKi) have transformed treatment for people with chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and other B-cell malignancies. …
CME credits: 0.50 Valid until: 22-03-2024 Claim your CME credit at https://reachmd.com/programs/cme/schizophrenia-and-bipolar-disorder-improving-adherence-and-new-therapeutic-updates/14991/ Schizophrenia affects an estimated 21 million people worldwide, and bipolar disorder (BPD) is the sixth leading cause of disability. These are chronic psychiatr…
R
ReachMD CME
1
Battle of the Biomarkers: Assessing Key Factors in Prognosis, Monitoring, & Therapeutic Decision-Making for Disease Worsening in Multiple Sclerosis
CME credits: 1.00 Valid until: 21-03-2024 Claim your CME credit at https://reachmd.com/programs/cme/battle-of-the-biomarkers-assessing-key-factors-in-prognosis-monitoring-therapeutic-decision-making-for-disease-worsening-in-multiple-sclerosis/14683/ Over the past several years, the image of MS has been changing from distinct categories of disease t…
R
ReachMD CME
CME credits: 0.25 Valid until: 15-03-2024 Claim your CME credit at https://reachmd.com/programs/cme/dont-let-hyperkalemia-get-you-down-when-potassium-goes-up-in-your-patients-with-heart-failure/13258/ In heart failure, there is a propensity to down-titrate or discontinue guideline-directed medical therapy in the presence of hyperkalemia, even thoug…
CME credits: 0.50 Valid until: 15-03-2024 Claim your CME credit at https://reachmd.com/programs/cme/altering-the-course-of-type-1-diabetes-prevention-trials/14287/ Autoantibody Screening to Identify Risk for Type 1 Diabetes T1D defines a continuum that begins during an asymptomatic prodrome before the disease manifests clinically. One of the challe…
CME credits: 0.25 Valid until: 07-03-2024 Claim your CME credit at https://reachmd.com/programs/cme/cervical-cancer-screening-the-case-of-the-young-patient/14673/ Explore the case of a young patient to see the ACS and ASCCP cervical cancer screening guidelines in action. Who needs to be screened, how is it best to screen, and what's the best test? …
CME credits: 0.25 Valid until: 28-02-2024 Claim your CME credit at https://reachmd.com/programs/cme/parallels-between-kidney-transplantation-and-maternal-anti-fetal-rejection/13911/ Program Chairman: Roberto Romero, MD, DMedSci Chief, Perinatology Research Branch Division of Maternal-Fetal Medicine and Obstetrics Division of Intramural Research NIC…
CME credits: 0.25 Valid until: 28-02-2024 Claim your CME credit at https://reachmd.com/programs/cme/personalizing-the-treatment-of-recurrentmetastatic-hnscc-a-multifactorial-path/14953/ KEYNOTE-048 has opened new vistas to managing patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Nonetheless, uncertainties remai…
CME credits: 0.25 Valid until: 28-02-2024 Claim your CME credit at https://reachmd.com/programs/cme/molecular-driven-treatment-advances-in-her2-metastatic-colorectal-cancer/14949/ Are you familiar with the most recent clinical data surrounding the treatment of HER2-positive metastatic colorectal cancer? Listen in as Drs. Tanios Bekii-Saab and Jolee…
CME credits: 1.00 Valid until: 17-02-2024 Claim your CME credit at https://reachmd.com/programs/cme/treatment-of-patients-with-established-vte-with-cancer-and-covid-19/14723/ There is not a “one size fits all approach” for managing cancer-associated venous thrombosis (CAT), as each patient reports unique challenges. In the face of multiple options …
CME credits: 1.00 Valid until: 17-02-2024 Claim your CME credit at https://reachmd.com/programs/cme/treatment-of-a-patient-with-cancer-and-with-catheter-related-thrombosis/14726/ There is not a “one size fits all approach” for managing cancer-associated venous thrombosis (CAT), as each patient reports unique challenges. In the face of multiple opti…
R
ReachMD CME
CME credits: 1.00 Valid until: 17-02-2024 Claim your CME credit at https://reachmd.com/programs/cme/prophylaxis-of-medically-treated-patient-with-cancer-and-reduced-mobility-in-hospital/14722/ There is not a “one size fits all approach” for managing cancer-associated venous thrombosis (CAT), as each patient reports unique challenges. In the face of…
CME credits: 1.00 Valid until: 17-02-2024 Claim your CME credit at https://reachmd.com/programs/cme/how-do-we-make-sense-of-guidelines-and-apply-to-our-everyday-practice/14728/ There is not a “one size fits all approach” for managing cancer-associated venous thrombosis (CAT), as each patient reports unique challenges. In the face of multiple option…
R
ReachMD CME
CME credits: 1.00 Valid until: 17-02-2024 Claim your CME credit at https://reachmd.com/programs/cme/treatment-of-patient-with-low-risk-of-genitourinary-bleed-for-established-vte-with-cancer/14724/ There is not a “one size fits all approach” for managing cancer-associated venous thrombosis (CAT), as each patient reports unique challenges. In the fac…
R
ReachMD CME
1
Treatment of Patient With Low Risk of Gastrointestinal Absorption Impairment for Established VTE With Cancer
CME credits: 1.00 Valid until: 17-02-2024 Claim your CME credit at https://reachmd.com/programs/cme/treatment-of-patient-with-low-risk-of-gastrointestinal-absorption-impairment-for-established-vte-with-cancer/14725/ There is not a “one size fits all approach” for managing cancer-associated venous thrombosis (CAT), as each patient reports unique cha…
R
ReachMD CME
1
Primary Thromboprophylaxis of Patient at High-Risk of VTE Who Is Receiving Systemic Anticancer Therapy
CME credits: 1.00 Valid until: 17-02-2024 Claim your CME credit at https://reachmd.com/programs/cme/primary-thromboprophylaxis-patient-high-risk-vte-who-receiving-systemic-anticancer-therapy/14727/ There is not a “one size fits all approach” for managing cancer-associated venous thrombosis (CAT), as each patient reports unique challenges. In the fa…
R
ReachMD CME
1
Recent Advances and Emerging Approaches in the Treatment of Recurrent/Metastatic SCCHN: Matching the Patient to the Optimal Therapy
CME credits: 0.25 Valid until: 13-02-2024 Claim your CME credit at https://reachmd.com/programs/cme/recent-advances-and-emerging-approaches-in-the-treatment-of-recurrentmetastatic-scchn-matching-the-patient-to-the-optimal-therapy/14495/ While key clinical trials inform our management philosophy for patients with recurrent/metastatic squamous cell c…
R
ReachMD CME
CME credits: 0.75 Valid until: 10-02-2024 Claim your CME credit at https://reachmd.com/programs/cme/what-is-the-latest-real-world-evidence-with-cdk46-inhibitors-in-metastatic-hr-breast-cancer/14783/ The introduction of cyclin-dependent kinase (CDK) 4/6 inhibitors has drastically changed the treatment landscape of hormone receptor-positive/human epi…
R
ReachMD CME
1
How Does RWE Expand Understanding of CDK4/6 Inhibitor Use in Special Populations With HR+/HER2- Metastatic Breast Cancer?
CME credits: 0.75 Valid until: 10-02-2024 Claim your CME credit at https://reachmd.com/programs/cme/how-does-rwe-expand-understanding-of-cdk46-inhibitor-use-in-special-populations-with-hrher2-metastatic-breast-cancer/14784/ The introduction of cyclin-dependent kinase (CDK) 4/6 inhibitors has drastically changed the treatment landscape of hormone re…
R
ReachMD CME
1
Interpretation and Application of RWE to Inform Shared Decision-Making in Metastatic HR+ Breast Cancer
CME credits: 0.75 Valid until: 10-02-2024 Claim your CME credit at https://reachmd.com/programs/cme/interpretation-and-application-of-rwe-to-inform-shared-decision-making-in-metastatic-hr-breast-cancer/14785/ The introduction of cyclin-dependent kinase (CDK) 4/6 inhibitors has drastically changed the treatment landscape of hormone receptor-positive…
R
ReachMD CME
1
Paradigm Shifts in CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: A Video Viewpoint
CME credits: 0.25 Valid until: 07-02-2024 Claim your CME credit at https://reachmd.com/programs/cme/paradigm-shifts-in-car-t-cell-therapy-for-relapsedrefractory-large-b-cell-lymphoma-a-video-viewpoint/14588/ Since the first chimeric antigen receptor (CAR) T-cell therapy was approved by the US Food and Drug Administration (FDA) for the treatment of …
R
ReachMD CME
1
Paradigm Shifts in CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: A Video Panel Discussion
CME credits: 0.50 Valid until: 07-02-2024 Claim your CME credit at https://reachmd.com/programs/cme/paradigm-shifts-in-car-t-cell-therapy-for-relapsedrefractory-large-b-cell-lymphoma/14589/ Since the first chimeric antigen receptor (CAR) T-cell therapy was approved by the US Food and Drug Administration (FDA) for the treatment of large B-cell lymph…
R
ReachMD CME
CME credits: 0.25 Valid until: 01-02-2024 Claim your CME credit at https://reachmd.com/programs/cme/titrating-and-dosing-device-therapy-for-dre-best-practices-for-optimizing-patient-outcomes/14854/ Vagus nerve stimulation (VNS) therapy is an add-on neuromodulation treatment designed for adults and children diagnosed with drug-resistant epilepsy (DR…
